Xavier Becerra, Secretary of the U.S. Department of Health and Human Services, ordered the Centers for Medicare and Medicaid Services (CMS) Monday to reconsider the massive Medicare Part B premium hike scheduled to begin this month.
More than half of this increase was due to the exorbitant price of just one prescription drug for Alzheimer’s, Aduhelm, that has not even been approved for use by Medicare.
Medicare officials announced hours after Secretary Becerra’s directive on Tuesday that coverage of Aduhelm would be limited to patients who receive it in randomized controlled trials. The decision marks the first time Medicare has limited beneficiaries access to an FDA-approved drug in this way. On December 14, the Alliance sent a letter asking Secretary Becerra to reverse the excessive premium increase.
“Seniors simply cannot afford the Part B increase, nearly half of which is due to the outrageous price of one controversial drug,” said Richard Fiesta, Executive Director of the Alliance. “We are grateful that Secretary Becerra has done what Alliance members asked: tell CMS to reconsider its decision.”
Medicare beneficiaries were shocked to learn last year that their Medicare Part B premiums are scheduled to go up by $21.70 per month in 2022, a 14.55% increase over last year’s premium. CNN reported in November that $10 of the planned increase was due to Aduhelm, at a cost of $56,000 per year per patient. The higher premiums, which are deducted from beneficiaries’ Social Security checks, would have cost consumers a significant portion of this year’s 5.9% cost-of-living increase.
Making matters worse, pharmaceutical corporations have already hiked prices for hundreds of drugs by nearly 5% this year, leading Fiesta to declare Aduhelm part of a bigger problem.
“Americans pay the highest prices in the world for prescription drugs, and seniors are bearing the brunt of it,” Fiesta stated. “It is unconscionable for Medicare premiums to increase this dramatically because of one corporation’s greed. This illustrates why Congress must take strong action to rein in the drug corporations and allow Medicare to negotiate lower drug prices for the American people.”